What one share of Inhibitor Therapeutics holds
February 2026, with support from Frameshift Management, Inc. (“Frameshift”), we submitted a formal meeting request and briefing materials to the U.S. Food and Drug Administration (“FDA”) regarding our proposed development pathway for itraconazole in
Inhibitor Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.02 |
|---|---|
| Cash and investments | $0.00 |
| Debt | $0.00 |
| Book value | −$0.01 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2012 | — | $0.01 | — | — | — | −$0.01 |
| 2013 | $0.00 | −$0.10 | — | — | — | −$0.04 |
| 2014 | $0.00 | −$0.04 | — | — | — | — |
| 2015 | $0.00 | −$0.02 | — | — | — | $0.00 |
| 2016 | $0.00 | −$0.02 | — | — | — | $0.02 |
| 2017 | $0.00 | −$0.01 | — | — | — | $0.00 |
| 2018 | $0.00 | −$0.01 | — | — | — | $0.00 |
| 2019 | $0.00 | −$0.01 | — | — | — | −$0.01 |
| 2020 | $0.00 | −$0.00 | — | — | — | −$0.01 |
| 2021 | $0.00 | −$0.00 | — | — | — | −$0.01 |
| 2022 | — | $0.03 | — | — | — | — |
| 2023 | — | −$0.02 | — | — | — | $0.03 |
| 2024 | — | −$0.02 | — | — | — | $0.01 |
| 2025 | — | −$0.02 | — | — | — | −$0.01 |
Common questions about Inhibitor Therapeutics
How much does one share of Inhibitor Therapeutics earn?
Over the last 12 months, Inhibitor Therapeutics lost $0.02 for each share.
Does Inhibitor Therapeutics pay a dividend?
Inhibitor Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Inhibitor Therapeutics’s book value per share?
Inhibitor Therapeutics’s book value is negative (−$0.01 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Inhibitor Therapeutics have?
Each share of Inhibitor Therapeutics has $0.00 of cash and investments and $0.00 of debt, as of June 30, 2026.
Has Inhibitor Therapeutics bought back shares?
Inhibitor Therapeutics’s share count rose about 1164% from 2012 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.